65G:F:F-NEXTCELL PHARMA AB (EUR)

COMMON STOCK | Biotechnology |

Last Closing

USD 0.0738

Change

0.00 (-4.40)%

Market Cap

USD 7.93M

Volume

N/A

Analyst Target

N/A
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2024-07-11 )

Largest Industry Peers for Biotechnology

Symbol Name Price(Change) Market Cap
NOVA:F Novo Nordisk A/S

N/A

USD 521.27B
RGO:F Regeneron Pharmaceuticals Inc

N/A

USD 108.70B
CSJ:F CSL Limited

N/A

USD 89.71B
CSJA:F CSL LTD SPON.ADR 2

N/A

USD 89.56B
0QF:F Moderna Inc

N/A

USD 30.85B
UNC0:F UCB S.A. UNSP.ADR 1/2

N/A

USD 28.92B
1AEA:F argenx SE

N/A

USD 28.10B
1AE:F Argen-X

N/A

USD 28.01B
DUL:F Alnylam Pharmaceuticals Inc

N/A

USD 27.60B
22UA:F BioNTech SE

N/A

USD 17.88B

ETFs Containing 65G:F

ITKY:LSE iShares II Public Limited.. 6.49 % 0.00 %

N/A

USD 0.13B
IQQ5:XETRA iShares MSCI Turkey UCITS.. 6.25 % 0.00 %

N/A

USD 0.10B
HTRY:SW 5.33 % 0.00 %

N/A

N/A
FEM:LSE First Trust Emerging Mark.. 1.65 % 0.00 %

N/A

USD 0.01B
FEMU:LSE First Trust Global Funds .. 1.65 % 0.00 %

N/A

USD 0.01B
FEM First Trust Emerging Mark.. 1.61 % 0.80 %

N/A

USD 0.43B
TUR iShares MSCI Turkey ETF 0.00 % 0.59 %

N/A

N/A
HTRY:LSE 0.00 % 0.00 %

N/A

N/A
IDTK:LSE iShares MSCI Turkey UCITS 0.00 % 0.00 %

N/A

N/A
HTRD:LSE 0.00 % 0.00 %

N/A

N/A
HTR:PA 0.00 % 0.00 %

N/A

N/A
H4ZK:F 0.00 % 0.00 %

N/A

N/A
IQQ5:F iShares II Public Limited.. 0.00 % 0.00 %

N/A

N/A
H4ZK:XETRA 0.00 % 0.00 %

N/A

N/A

Market Performance

  Market Performance vs. Industry/Classification (Biotechnology) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain -62.82% 9% A- 4% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -62.82% 9% A- 4% F
Trailing 12 Months  
Capital Gain -78.61% 9% A- 4% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -78.61% 9% A- 4% F
Trailing 5 Years  
Capital Gain N/A N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return N/A N/A N/A N/A N/A
Average Annual (5 Year Horizon)  
Capital Gain -22.15% 19% F 7% C-
Dividend Return -22.15% 19% F 6% D-
Total Return N/A N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) 32.70% 49% F 36% F
Risk Adjusted Return -67.74% 20% F 9% A-
Market Capitalization 7.93M 15% F 9% A-

Annual Financials (EUR)

Quarterly Financials (EUR)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:

There is nothing we particularly like

What to not like:
Poor risk adjusted returns

This company is delivering below median risk adjusted returns in its peers. Even if it is outperforming on returns , the returns are unpredictable. Proceed with caution.

Below median dividend returns

The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.

High volatility

The total returns for this company are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.

Low market capitalization

This is among the smaller entities in its sectors with below median market capitalization. That may make it less stable in the long run unless it has a unique technology or market which can help it grow or get acquired in future.

Negative free cash flow

The company had negative total free cash flow in the most recent four quarters.